{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-003193","form_type":"8-K","ticker":"PVCT","cik":"0000315545","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","filed_at":"2025-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.944533+00:00","generated_at":"2026-05-27T21:20:06.523633+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Provectus Biopharma approves up to $10M convertible loan financing for drug development","bullets":["Board approved 2025 Term Sheet to arrange up to $10M unsecured convertible loan in tranches.","Loan bears 8% annual interest; principal and interest convertible into Series D-1 Preferred at $2.8620 per share, each convertible into 10 common shares.","Proceeds to fund drug discovery and development program and general & administrative expenses.","Company closed 2024 Financing with $1M in convertible promissory notes received as of January 15, 2025.","Issuance of notes exempt from registration under Section 4(a)(2) or Rule 506 of Regulation D."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-003193","json":"https://secwatch.observer/filing/0001493152-25-003193.json","markdown":"https://secwatch.observer/filing/0001493152-25-003193.md","text":"https://secwatch.observer/filing/0001493152-25-003193.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/315545/000149315225003193/0001493152-25-003193-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/315545/000149315225003193/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T21:20:06.523633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}